Tivantinib alleviates inflammatory diseases by directly targeting NLRP3

NLRP3 inflammasome-mediated immune responses are involved in the pathogenesis of multiple inflammatory diseases, but few clinical drugs are identified that directly target the NLRP3 inflammasome to treat these diseases to date. Here, we show that the anticancer agent tivantinib is a selective inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi, Guo, Yun, Zhou, Yan, Huang, Qian, Ru, Yi, Luo, Yingli, Xu, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950949/
https://www.ncbi.nlm.nih.gov/pubmed/36843841
http://dx.doi.org/10.1016/j.isci.2023.106062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950949/
https://www.ncbi.nlm.nih.gov/pubmed/36843841
http://dx.doi.org/10.1016/j.isci.2023.106062

Ejemplares similares